(Total Views: 741)
Posted On: 01/29/2021 4:24:31 PM
Post# of 149272
For me, this was the most significant news coming out of today's (or last night's presentation). It should lay to rest several nagging questions:
- Dr. Janet Woodcock is a proponent. Significant upgrade from Dr. Hahn.
- The FDA is not slow walking leronlimab for Covid. The FDA truly were waiting for CD12 full trial results to act. And this sense of urgency is clealy being displayed.
- With both Amerex and FDA biostatisticians working in parallel, results will come out sooner rather than later. Correspondingly, any potential EUA and/or full approval will be expedited since the FDA will already be familiar with the trial results and won't need to take time to go over Amerex's report.
- Dr. Janet Woodcock is a proponent. Significant upgrade from Dr. Hahn.
- The FDA is not slow walking leronlimab for Covid. The FDA truly were waiting for CD12 full trial results to act. And this sense of urgency is clealy being displayed.
- With both Amerex and FDA biostatisticians working in parallel, results will come out sooner rather than later. Correspondingly, any potential EUA and/or full approval will be expedited since the FDA will already be familiar with the trial results and won't need to take time to go over Amerex's report.
(15)
(0)Scroll down for more posts ▼
